Enhancing the Immunogenicity of a Dengue-2 DNA Vaccine With Adjuvants and Anti-FC(Gamma)RI Antibodies
Abstract
The overall objective of the project is to use adjuvants to enhance the immunogenicity of a dengue DNA vaccine. The adjuvants to be evaluated in this project include aluminum phosphate, tetanus toxoid and anti-FcgammaR monoclonal antibodies chemically linked to the DNA vaccine. The protocol for linking the monoclonal antibodies to the dengue DNA vaccine was finalized. Anti-FcgammaRI antibodies were obtained from Accurate Chemical, Wesbury, NY. Anti- FcgammaRII and FcgammaRIII monoclonal antibodies were also obtained and evaluated. Indirect immunofluorescence assays (IFA) were performed to confirm recognition of Fcgamma receptors on K562 cells (human monocyte cell line) and P388D1 cells (mouse monocyte cell line) prior to linking to the dengue DNA vaccine. Experimental results indicated poor recognition of the Fcgamma receptors by these monoclonal antibodies. Anti-FcgammaRI and anti-FcgammaRII monoclonal antibodies were obtained from Pharmingen Inc., San Diego, CA and evaluated. IFA confirmed recognition of the anti- FcgammaRII receptors but not FcgammaRI receptors on K562 cells. The P388D I mouse cells showed no reactivity with either antibody. IFA antibody binding results are currently being confirmed by flow cytometry analysis. Upon final approval of the animal use protocol, mouse studies will begin to evaluate the adjuvant effects of aluminum phosphate and tetanus toxoid.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2002
- Accession Number
- ADA412791
Entities
People
- Kanakatte Raviprakash
- Kevin R. Porter
- Shuenn-jue Wu
Organizations
- Naval Medical Research Center